Expert Insight

Content

Why Your Monodisperse PEG Purity Specification Could Be Putting Your ADC or Peptide Program at Risk

24 April 2026

Expert Insight

Regulatory Insights for Sterile Fill Finish Facilities

22 April 2026

Expert Insight

Eramol on Navigating Sterile Fill-Finish Compliance for Early-Phase Biotechs

20 April 2026

Content

Fill-Finish is never ‘Just’ Fill Finish

14 April 2026

Expert Insight

Gates MRI Takes the Stage at CDMO Live Europe 2026: Advancing Access to Therapeutics and Vaccines Through Strategic Partnerships

12 April 2026

Content

How pharmaceutical manufacturers and their CDMO partners can close the Scope 3 data gap

10 April 2026

Content

What Does it Take to Bring ADCs to Patients: Connecting Early Biology to Long-Term Program Success

9 April 2026

Expert Insight

Peptide Synthesis Strategy for Late-Stage Development: What Biotech and Pharma Buyers Need to Know

1 April 2026

Expert Insight

Why AAV Programs Fail to Scale and What Academics Need to Do Differently

27 March 2026

Expert Insight

What Cell Therapy Biotechs Get Wrong When Selecting a CDMO

25 March 2026